ACTG 243--PHASE II STUDY COMPARING ANTIRETROVIRAL THERAPY ALONE OR WITH ARA-C

ACTG 243——比较单独抗逆转录病毒治疗或与 ARA-C 治疗的 II 期研究

• 批准号: 6246239
• 负责人: HENRY S SACKS
• 金额: $ 4.47万
• 依托单位: MOUNT SINAI SCHOOL OF MEDICINE OF CUNY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-12 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6246239
• 关键词: AIDS therapy; HIV infections; antiAIDS agent; antiviral agents; chemoprevention; clinical research; combination chemotherapy; cytosine arabinoside; drug screening /evaluation; human morbidity; human subject; human therapy evaluation; longitudinal human study; nervous system disorder chemotherapy; progressive multifocal leukoencephalopathy

This is a randomized open-label study which will compare the efficacy of antiretroviral therapy vs. antiretroviral therapy plus cytosine arabinoside (Ara-C) in the prevention of death during study follow-up in HIV-infected individuals who have developed progressive multifocal leukoencelphalopathy (PML).

这是一项随机开放研究，将比较 抗逆转录病毒治疗与抗逆转录病毒加胞嘧啶治疗的比较 阿糖胞苷(Ara-C)在预防研究期间死亡中的作用 已发展为进行性多灶性感染的艾滋病毒感染者 白质脑病(PML)。